SCHEMBL1879389

SCHEMBL1879389

CC(C)C(=O)NC1CCc2[nH]c3c(F)cc(Br)cc3c2C1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 1/20 0.41
MTNR1B P49286 1/20 0.41
HTR1A P08908 2/20 0.39
HTR1B P28222 2/20 0.39
HTR1D P28221 1/20 0.39
KMT2A Q03164 3/20 0.37
MEN1 O00255 2/20 0.37
IKBKB O14920 1/20 0.37
USP2 O75604 1/20 0.37
ALDH1A1 P00352 1/20 0.37
TP53 P04637 1/20 0.37
MAPT P10636 1/20 0.37
ALOX15 P16050 1/20 0.37
MAPK1 P28482 1/20 0.37
MAPK10 P53779 1/20 0.37
HSD17B10 Q99714 1/20 0.37
DRD2 P14416 1/20 0.35
DRD4 P21917 1/20 0.35
HTR1E P28566 1/20 0.35
HTR7 P34969 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7415604 0.89 MTNR1A (0.42) MTNR1AMTNR1BHTR1AHTR1BHTR1D
SCHEMBL1878640 0.82 HTR1B (0.44) MTNR1AMTNR1BHTR1AHTR1BHTR1D
SCHEMBL1876695 0.81 HTR1A (0.54) HTR1AHTR1BHTR1DKMT2AMEN1
SCHEMBL1876698 0.81 HTR1A (0.54) HTR1AHTR1BHTR1DKMT2AMEN1
SCHEMBL1877210 0.77 HTR1A (0.54) MTNR1AMTNR1BHTR1AHTR1BHTR1D
SCHEMBL14623596 0.77 HTR1B (0.41) MTNR1AMTNR1BHTR1AHTR1BHTR1D
SCHEMBL7408004 0.77 APOL1 (0.43) MTNR1AMTNR1BHTR1AHTR1BHTR1D
SCHEMBL14624157 0.75 HTR1B (0.48) MTNR1AMTNR1BHTR1AHTR1BHTR1D
SCHEMBL1881308 0.75 MTNR1A (0.40) MTNR1AMTNR1BHTR1AHTR1BHTR1D
SCHEMBL11344966 0.73 APOL1 (0.38) HTR1AHTR1BHTR1DDRD2DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7935722-B2 Tetrahydrocarbazole derivatives useful as androgen receptor modulators ELI LILLY AND COMPANY (US) 2011-05-03 US disclosed
US-7935722-B2 Tetrahydrocarbazole derivatives useful as androgen receptor modulators ELI LILLY AND COMPANY (US) 2011-05-03 US disclosed
US-7935722-B2 Tetrahydrocarbazole derivatives useful as androgen receptor modulators ELI LILLY AND COMPANY (US) 2011-05-03 US disclosed
EP-1902026-B1 TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS (SARM) LILLY CO ELI (US) 2010-02-17 EP disclosed
US-20100022550-A1 TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS CELLECTIS (FR) 2010-01-28 US disclosed
US-20100022550-A1 TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS CELLECTIS (FR) 2010-01-28 US disclosed
US-20100022550-A1 TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS CELLECTIS (FR) 2010-01-28 US disclosed
EP-1902026-A2 TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS (SARM) ELI LILLY AND COMPANY (US) 2008-03-26 EP disclosed
WO-2007002181-A2 TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS (SARM) ELI LILLY AND COMPANY (US) 2007-01-04 WO disclosed
WO-2007002181-A2 TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS (SARM) ELI LILLY AND COMPANY (US) 2007-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022550-A1 TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS AR, SHBG, CYP17A1 MTNR1A 1610/4885MTNR1B 1349/4885HTR1A 1299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.